Search

Your search keyword '"HSP90 Heat-Shock Proteins antagonists & inhibitors"' showing total 2,794 results

Search Constraints

Start Over You searched for: Descriptor "HSP90 Heat-Shock Proteins antagonists & inhibitors" Remove constraint Descriptor: "HSP90 Heat-Shock Proteins antagonists & inhibitors"
2,794 results on '"HSP90 Heat-Shock Proteins antagonists & inhibitors"'

Search Results

1. HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids.

2. Chaperoning system: Intriguing target to modulate the expression of CFTR in cystic fibrosis.

3. Extracellular heat shock protein 90 alpha (eHsp90α)'s role in cancer progression and the development of therapeutic strategies.

4. The beneficial effects of the active components from Maclura tricuspidata fruits in the treatment of diabetes mellitus.

5. 1G6-D7 Inhibits Homologous Recombination Repair by Targeting Extracellular HSP90α to Promote Apoptosis in Non-Small Cell Lung Cancer.

6. Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry.

7. Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy.

8. Development and Preclinical Evaluation of 18 F-Labeled PEGylated Sansalvamide A Decapeptide for Noninvasive Evaluation of Hsp90 Status in Pancreas Cancer.

9. Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents.

10. Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer.

11. HSP90β shapes the fate of Th17 cells with the help of glycolysis-controlled methylation modification.

12. Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials.

13. Investigation of the site 2 pocket of Grp94 with KUNG65 benzamide derivatives.

14. ClassIIb histone deacetylase participates in perioperative neurocognitive disorders in elderly mice via HSP90/GR signaling pathway.

15. HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression.

16. The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice.

17. Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects.

18. Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis.

19. Allosteric Activation of Protein Phosphatase 5 with Small Molecules.

20. Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer.

21. Small molecule inhibitors targeting heat shock protein 90: An updated review.

22. Antiproliferative Impact of Linagliptin on the Cervical Cancer Cell Line.

23. Synthesis and characterization of 64 Cu-labeled Geldanamycin derivative for imaging HSP90 expression in breast cancer.

24. Novel tropane analogues as Hsp90 inhibitors targeting colon cancer: Synthesis, biological estimation, and molecular docking study.

25. A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer.

26. Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation.

27. Activity-based protein profiling and global proteome analysis reveal MASTL as a potential therapeutic target in gastric cancer.

28. Structural Characterization of Heat Shock Protein 90β and Molecular Interactions with Geldanamycin and Ritonavir: A Computational Study.

29. New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer.

30. Repurposing Hsp90 inhibitors as antimicrobials targeting two-component systems identifies compounds leading to loss of bacterial membrane integrity.

31. GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition.

32. Pimitespib, a Novel Heat Shock Protein 90 Inhibitor, Is Effective in Treating Renal Cell Carcinoma by Anti-angiogenetic Signaling.

33. Synthesis of C3'-Foused Aryl/Penta-1,4-Dien-3-One/Amine Hybrids as HSP90C-Terminal Inhibitors.

34. HDAC6 modulates the cognitive behavioral function and hippocampal tissue pathological changes of APP/PS1 transgenic mice through HSP90-HSF1 pathway.

35. Exploration and optimisation of structure-activity relationships of new triazole-based C-terminal Hsp90 inhibitors towards in vivo anticancer potency.

36. An update on the status of HSP90 inhibitors in cancer clinical trials.

37. Comprehensive analysis of resorcinyl-imidazole Hsp90 inhibitor design.

38. Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells.

39. Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line.

40. Enhancing Magnetic Hyperthermia Efficacy through Targeted Heat Shock Protein 90 Inhibition: Unveiling Immune-Mediated Therapeutic Synergy in Glioma Treatment.

41. Expanded ROS Generation and Hypoxia Reversal: Excipient-free Self-assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy.

42. Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.

43. Probing some recent natural compounds from Phellinus baumii , Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors.

44. A novel combination therapy targets sonic hedgehog signaling by the dual inhibition of HMG-CoA reductase and HSP90 in rats with non-alcoholic steatohepatitis.

45. "Cicada Out of the Shell" Deep Penetration and Blockage of the HSP90 Pathway by ROS-Responsive Supramolecular Gels to Augment Trimodal Synergistic Therapy.

46. Inhibiting spinal cord-specific hsp90 isoforms reveals a novel strategy to improve the therapeutic index of opioid treatment.

47. Novel Oridonin Analog CYD0682 Inhibits Hepatic Stellate Cell Activation via the Heat Shock Protein 90-Dependent STAT3 Pathway.

48. A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.

49. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.

50. JD-02, a novel Hsp90 inhibitor, induces ROS/SRC axis-dependent cytoprotective autophagy in colorectal cancer cells.

Catalog

Books, media, physical & digital resources